To view this email as a web page, click here.

You are subscribed to the FormularyWatch eNews.

FormularyWatch

Share

eNews Subscribe

More Subscriptions

FORMULARY WATCH

CHOLESTEROL DRUGS

TODAY'S HEADLINES

How Express Scripts will manage pricey cholesterol drugs

By Christine Blank
Express Scripts said this week it will now include Praluent and Repatha in its National Preferred Formulary. How they'll do it

Top 3 additions to IPF treatment guidelines

by Christine Blank
Pulmonary fibrosis organizations and healthcare providers are lauding the update of the Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis, which was last updated in 2011. What's new?

CONTINUING EDUCATION

MTM essentials for allergic rhinitis management

Session code: 15DT34-XVK37
This month’s CE activity is part of the CPE series, "Medication Therapy Management for the Patient with Respiratory Disease." From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and  Drug Topics.

The goal of this month's activity is to discuss the pathophysiology and clinical presentation of allergic rhinitis and review nonpharmacologic and pharmacologic treatments for the symptoms of allergic rhinitis.

To read and print the article with TEST QUESTIONS,  click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT34-XVK37.
Copy the session code — 15DT34-XVK37 — before logging into the  Online CE Center. When the page for the Online CE Center opens, paste the session code into the appropriate field, under your NABP ID.

EDITOR'S PICK

Visterra gets major funding to develop novel flu drug

by Christine Blank
A novel influenza drug will advance in development, thanks to funding from the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response. Read more

October 09, 2015

Related Articles

FDA approves major cholesterol drug

New study highlights benefits of nintedanib in IPF treatment

Resources

Get the latest FormularyWatch updates on drug approvals, current studies, and other findings.

Click for the latest Clinical News

Click to contact the editorial team. Click to contact the sales team.

Part of the

ModernMedicine logo

This email was sent by: %%Member_Busname%%
%%Member_Addr%%
%%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%

 

NEWSLETTER

Forward to a Friend
Privacy Statement
Terms of Service
Update Profile
Add/Remove Newsletters